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THE ENDOCANNABINOID SYSTEM
The identification, in the mid-1960s, of the major psy-
cochoactive component of Cannabis sativa and mari-
juana (Δ9-tetrahydrocannabinol, Δ9 THC) and the dis-
covery of its membrane receptors, paved the way to re-
veal a whole endogenous signaling system known as
the endocannabinoid (EC) system (7).
Several studies have demonstrated the role of the EC
system in physiological functions, such as homeostasis
and stress response. EC have neuroprotective and anal-
gesic properties, controlling movement and some mem-
ory processes (8, 9). Moreover, the EC system modu-
lates immune, endocrine and inflammatory response.
Finally, EC influence the pulmonary and cardiovascular
system, controlling blood pressure and heart rhythm
and having bronchodilatating properties (6-9).
Endocannabinoids
Anandamide (N-arachidonoyl-ethanolamine (AEA))
and 2-arachidonoyl-glycerol (2-AG) are the most stud-
ied EC, but recently new synthetic and non-synthetic
molecules have been proposed as cannabinoid recep-
tor agonists (Fig. 1) (6, 7).
It is well established that AEA and 2-AG are not pre-
stored in secretory vesicles but are de novo biosynthe-
sized following an increase in the intracellular concen-
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ABSTRACT: The prevalence of obesity continues to increase and represents one of the principal
causes of cardiovascular morbidity and mortality. After the discovery of a specific receptor of the
psychoactive principle of marijuana, the cannabinoid receptors and their endogenous ligands,
several studies have demonstrated the role of this system in the control of food intake and ener-
gy balance and its overactivity in obesity. Recent studies with the CB1 receptor antagonist ri-
monabant have demonstrated favorable effects such as a reduction in body weight and waist cir-
cumference and an improvement in metabolic factors (cholesterol, triglycerides, glycemia etc).
Therefore, the antagonism of the endocannabinoid (EC) system, if recent data can be confirmed,
could be a new treatment target for high risk overweight or obese patients. Obesity is a growing
problem that has epidemic proportions worldwide and is associated with an increased risk of
premature death (1-3). Individuals with a central deposition of fats have elevated cardiovascular
morbidity and mortality (including stroke, heart failure and myocardial infarction) and, because of
a growing prevalence not only in adults but also in adolescents, it was reclassified in AHA guide-
lines as a “major modifiable risk factor” for coronary heart disease (4, 5). Although first choice
therapy in obesity is based on correcting lifestyle (diet and physical activity) in patients with ab-
dominal obesity and high cardiovascular risk and diabetes, often it is necessary to use drugs
which reduce the risks. The EC system represents a new target for weight control and the im-
provement of lipid and glycemic metabolism (6, 7). (Heart International 2007; 3: 27-34)
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tration of calcium, within a framework of a metabolic re-
action involving phospholipid precursors (N-acyl-
phosphatidyl-ethanolamine and diacylglycerol) and
specific calcium-sensitive enzymes (phospholipasis D
and diacylglycerol lipasis). Therefore, the whole  EC
production is triggered “on demand”. EC are released
from the cell immediately after their biosynthesis and
then quickly removed from the extracellular space by a
rapid and selective cellular reuptake mechanism (not
yet clear). In particular, EC transport is not leaded by
transmembrane ionic gradients, but to passive diffusion
through a transporter not yet identified. Instead, EC
degradation consists of the hydrolysis of AEA to
ethanolamine and arachidonic acid by fatty acid amide
hydrolase (FAAH) and of 2-AG by monoacyl-glycerol li-
pases (6, 7).
Cannabinoid receptors
To date, only two cannabinoid receptors have been
cloned: the CB1 and CB2 receptors (8, 9). 
At first the CB1 receptor was thought to be expressed
just in the cortical brain region (neocortex, hippocampus,
amigdala), in the basal ganglia, in the mesolimbic system,
in the thalamus and hypothalamus and in the cerebellum:
neurons of these areas regulate the expression of orexi-
genic and anorexigenic signals (10, 11).
Recent studies have demonstrated that CB1 recep-
tors are expressed in peripheral cells and tissues con-
trolling energy homeostasis, including gut, liver
adipocytes, skeletal muscle and pancreas.
CB2 receptors are present in several immune cells
and blood cells where they participate in the regulation
of cytokine release and function (10). Nevertheless, CB2
receptors also develop functions in other cells such as
the cheratinocitis, the osteoclastis and the endocrine
pancreas.
Since CB2 agonists have no psychological effects on
central nervous system they have become the object of
numerous studies in the therapeutic use of cannabi-
noids, particularly as regards the analgesic, anti-inflam-
matory and antineoplastic effects.
Endocannabinoids act primarily at cannabinoid CB1
and/or CB2 receptors with different efficacy. Synthetic
cannabinoids have been created so as to act as highly
selective agonists or antagonists for CB1 or CB2 recep-
tors. Δ9-tetrahydrocannabinol and 2-AG approximately
have similar affinity for CB1 and CB2 receptors, while
the AEA has a marginal selectivity for CB1 receptors.
However, the effectiveness of the Δ9-THC and the AEA
is lower in CB2 receptor than in CB1 receptor (7).
Both receptors belong to the family of the receptors
coupled to the G protein (GPCRs). The intracellular sig-
naling events include:
1. inhibition of stimulus-induced adenylate cyclase and
subsequent impairment of cAMP/protein kinase A-
mediated short and long-term effects;
2. stimulation of mitogen-activated protein kinase sig-
naling;
3. in case of CB1 receptors, inhibition of voltage-gated
Ca2+ channels and stimulation of inwardly rectifying
G protein-coupled K+ channels;
4. in case of CB1, stimulation of phosphatidylinositol 3-
kinase and of intracellular Ca2+ mobilization (7).
ENDOCANNABINOID SYSTEM AND MODULATION OF
ENERGETIC BALANCE
The EC system participates in the modulation of the
so-called mechanisms of pleasure and the manipulation
of this system influences appetite. Elevated CB1 ex-
pression in cerebral areas involved in the control of
pleasure indicates a strong involvement of this system
in different psychological functions, regulated by these
regions of the brain, including appetite (10). 
Under these circumstances, the ingested food that
acts on the nervous fibers which connect the hindbrain
Fig. 1 - Endocannabinoids.Nodari et al
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and the midbrain to the hypothalamus influences
dopamine, opioids, serotonine and noradrenaline mod-
ulating appetite and satisfaction.
The most remarkable route of pleasure is represented
by the mesolimbic dopaminergic system. The study of
this system clearly shows the existence of an increase
of dopamine extracellular levels inside the accumbens
nucleus after the ingestion of tasty food. Psychoactive
drugs such as marijuana and ethanolol, but also pleas-
ant stimuli or tasty foods, are known to induce the re-
lease of dopamine in specific cerebral regions. At this
level, the existence of a relationship has also been
shown between the EC system and the oppioid and
serotoninergic system (12).
It is now widely accepted that EC released from de-
polarized post-synaptic neurons retrogradely activate
presynaptic CB1 receptors, thereby reducing both in-
hibitory (GABA mediated) and excitatory (glutamate me-
diated) neurotransmission. This property seems to par-
ticipate in EC regulation of the hypothalamic networks
and of the anorexigenic (arcuate nucleus expressing co-
caine-amphetamine regulated transcript – CART and
paraventricular nucleus expressing corticotrophin-re-
leasing hormone) and orexigenic signals (lateral hypoy-
halamus neurons containing melanin-concentrating-
hormone and orexins) (13-15).  
Signals coming from various peripheral organs such
as the liver, the gut and the adipose tissue direct hor-
monal and biochemical signals to the hypothalamus to
notify the central nervous system about nutritional
state. An example of this peripheral control is leptin, a
hormone produced only by adipose tissue able to inter-
act with specific receptors located in the hypothalamus
to carry an anorexigenic signal. The EC system is mod-
ulated by leptin too; it was demonstrated that acute
treatment with leptin reduces hypothalamic levels of
AEA and 2-AG in normal mice, but above all it was un-
derlined that, in mice made obese and hyperphagic by a
defect of the leptin signal, EC hypothalamic levels are
permanently and pathologically elevated (14, 15).
Finally, some experimental evidence indicated that
EC and CB1 receptors regulate energetic metabolism
through a peripheral action at the level of the adipose
tissue, liver and pancreas (16-18).
Cota et al (11) demonstrated for the first time that
wild-type rats exhibit significantly higher amounts of fat
mass than CB1 receptor deficient rats. In addition, CB1
receptors stimulate lipoprotein lipase; as a consequence
they activate lipogenesis, suggesting that EC contribute
to the accumulation of body fat not only stimulating food
intake, but also acting directly at the adipose tissue level. 
Recent studies in vitro on adipose cell cultures un-
derlined that CB1 receptors blockage induces an arrest
of adipocytis proliferation, while chronic stimulation of
these receptors induces differentiation of preadipocytis
to adipocytis, shown by the early appearance of the dif-
ferentiation marker PPAR (peroxisome proliferator acti-
vated receptor). These results confirm that EC actively
participate in adipogenesis and fat accumulation; how-
ever, it was observed that AEA is able to act on PPAR re-
ceptors, independently from CB1 receptors (7).
In the liver, CB1 receptors are expressed around the
centrolobular vein, where, stimulating the expression of
SREBP-1c (steroid regulatory element binding protein
1-c) and its target (acetilCoA-carboxylase 1 and fatty
acid synthase), they activate lipogenesis and fatty acid
synthesis (7).
More recently, it was observed that EC are able to
regulate insulin levels, peripheral glucose uptake; and
therefore, to increase glucose tolerance. EC through
CB1 activation, would seem to be able to modify the se-
cretion of Ca2+ and, therefore, of insulin (19). Neverthe-
less, further studies will be necessary to define the role
of the EC system in the pancreas.
ENDOCANNABINOID OVERACTIVITY IN OBESITY
Obesity is probably a condition associated to the hy-
peractivity of the EC system. This recent hypothesis is
supported by a series of studies developed on animal
models of obesity; nevertheless, it still needs to be
demonstrated in humans.
It was demonstrated that the CB1 receptor is overex-
pressed in tissues which control energetic metabolism
such as the liver (18), skeletal muscles (9) and the adipose
organ (12, 16) when animals are made obese by a high fat
diet. In addition, the most important demonstration about
metabolism, is that the hyperactivation of the EC system
induces in  adipocyte cultures a reduction in the levels of
adiponectin and an increase in visfatin, two adipokines
having opposing roles. Adiponectin, a hormone pro-
duced only by adipose tissue, plays an important role in
the modulation of fat and glucose metabolism, becauseEndocannabinoids and cardiovascular prevention: real progress?
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it inhibits hepatic gluconeogenesis and controls free
fatty acid production, through the suppression of lipo-
genesis and the activation of fatty acid oxidation (16)
(Fig. 2).
It is still premature to express a judgment on the clin-
ical meaning of circulating levels of EC in humans and
the mechanisms that would stimulate overactivity of the
EC system in obesity remain unclear. 
In obese women, with no others comorbidities, and
whose cause of obesity was correlated to alimentary
disorders or to the menopause, AEA and 2-AG levels
were significantly greater than in the control group (17)
(Fig. 3). In addition, in patients affected by diabetes
mellitus type 2, EC levels were significantly greater than
in non-diabetic controls (20).
According to a recent study (21), a possible mecha-
nism of EC system hyperactivation would be represent-
ed by a reduced degradation of AEA; the authors identi-
fied in a population of obese subjects a polymorphism,
at the level of the FAAH sequence, the enzyme appoint-
ed to the degradation of AEA, which would behave as
reduced enzymatic activity (21). 
ENDOCANNABINOID SYSTEM ANTAGONISTS IN THE
TREATMENT OF OBESITY
The increasing evidence of the role of the EC system
in the regulation of food intake and energetic balance
has stimulated the development of CB1 receptor block-
ers, whose the most studied one in the treatment of
obesity is rimonabant (Fig. 4).
An extensive study of experimental phase III denom-
inated RIO (rimonabant in obesity), was conducted on
Fig. 2 - Effects of ri-
monobant on adiponectin
mRNA levels in lean and
obese rats and in CB1
knockout mice. 
Fig. 3 - Association between obesity and overactivity of the EC
system.Nodari et al
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about 6600 obese or overweight patients (22). This ex-
periment was composed of four substudies (RIO-North
America, RIO-Europe, RIO-Lipids and RIO-Diabetes) di-
rected to identify the effectiveness of rimonabant on
bodyweight as a primary end-point and on various
metabolic alterations such as secondary end-point. 
The pharmacological treatment, of 5 or 20 mg of ri-
monabant vs. placebo, was associated with a reduction
in energy intake of 600 calories in respect of basal
metabolic rate and to an increase in physical activity
(Fig. 5). In RIO-North America (23) compared to RIO-Eu-
rope (24), patients enrolled after the first year were re-
Fig. 4 - Possible action
mechanisms of CB1 re-
ceptor blockers and ri-
monabant effects.
Fig. 5 - Study design of RIO
(rimonabant in obesity).Endocannabinoids and cardiovascular prevention: real progress?
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randomized to placebo or rimonabant, for monitoring
possible resumption of body weight at the end of the
drug treatment. RIO-Lipids (25) and RIO-Diabetes (26)
were programmed for investigating the improvements
due to the administration of rimonabant, in patients that
were associated with obesity or with overweight dia-
betes and dyslipidemia, respectively.
In all studies, treatment with rimonabant 20 mg pro-
duced results significantly greater than 5 mg and the re-
sults were equivalent for primary and secondary end-
points.
The treatment with 20 mg rimonabant determined in
comparison to the placebo group a significant reduction
in body weight (8.7 vs. 2.8 kg in RIO-North America, 8.6
vs. 3.6 kg in RIO-Europe, 8.6 vs. 2.3 kg in RIO-Lipids,
6.1 vs. 1.9 kg in RIO-Diabetes) and of waist circumfer-
ence (8.5 vs. 4 cm in RIO-North America, 9 vs. 3 cm in
RIO-Europe, 9 vs. 4 cm in RIO-Lipids, 5.2 vs. 1.9 cm in
RIO-Diabetes) (Fig. 6). In the group treated with rimona-
bant a significant improvement in the lipidic profile was
also observed, with an increase in high-density lipopro-
tein (HDL) cholesterol, a reduction in triglycerides, and
an improvement in glycemia and insulinemia during oral
glucose tolerance test.
In RIO-Lipids, changes in leptin and adiponectin lev-
els were observed, demonstrating a significant de-
crease of leptin and an increase of the circulating levels
of adiponectin in patients treated with rimonabant. Mul-
tivariate analysis showed that rimonabant had indepen-
dent positive effects from weight loss on lipidic profile
and adiponectin levels. In RIO-Europe around 50% of
the variation in HDL cholesterol and in triglycerides was
independent from weight loss, while in the RIO-Lipids
the increase of 57% in adiponectin did not seem justifi-
able on the basis of caloric reduction only, but rather re-
lated to the peripheral action of rimonabant. 
In RIO-Diabetes, the HbA1 levels were lower in both
rimonabant groups compared to the placebo group and
showed a persistent reduction in the rimonabant 20 mg
group. In addition, it was possible to show that the re-
duction of HbA1 levels, that was two-fold higher than
the reduction due to weight loss, was independent from
the reduction in body weight, related to a peripheral ac-
tion of rimonabant.
Finally, in RIO-North America during the second year
of treatment in the group that continued with rimona-
bant, a continuous and progressive reduction in body
weight was observed, while in the group randomized to
placebo a recovery of most of the weight lost during the
first year was associated with an increase in triglyc-
erides and a reduction in HDL cholesterol.
Rimonabant was generally well tolerated and the
most frequent side effects were gastrointestinal (nausea
and diarrhea) and humoral (anxiety and depression).
CONCLUSIONS
The prevalence of obesity is continuously increasing
and represents one of the principal causes of cardio-
vascular morbidity and mortality. The recent discovery
of the role of the EC system in the control of energetic
metabolism and the presence of the overactivity of this
system in obesity, has enabled the development of new
drugs, antagonists of CB1 receptors such as rimona-
bant. These drugs are able not only to determine a re-
duction in body weight, but also to promote favorable
effects on lipidic and glycemic profiles, independently
from weight reduction.
Therefore, CB1 antagonists could represent a new
therapeutic option for the treatment of obesity and the
comorbidities related to it, when the currently available
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